As a founder and Managing Director of Correlation Ventures, David helps lead the firm, including managing its Life Science and Clean Tech investment practices.
David created the original vision for Correlation, driven by the opportunity to offer entrepreneurs and other VCs a better co-investment option and to pioneer the use of predictive analytics in venture capital. David began his venture capital career in 1997.
Prior to Correlation, David was a Managing Director of Hamilton BioVentures, an early-stage venture capital fund. As head of Hamilton’s Life Science team, David served on the Board of Directors of such companies as PhotoThera, Transcept (NASDAQ: TSPT), and Egea Biopharmaceuticals (Acquired by Johnson&Johnson).
Previously, David was a Venture Partner at Windamere Venture Partners and President of Forge Medical Ventures, an early-stage incubator funded by Enterprise Partners, Mayfield Fund and Johnson & Johnson Development Corporation.
Board & Advisor Roles (3)Update
|Jan 18, 2016||LifeSciVC | Recovering scientist turned early stage VC - Winners’ Circle: New Insights Into BioPharma Venture Returns|
|Apr 3, 2015||Venture Beat - With VCs riding unicorns just to collect their logos, we all stand to lose|
|Apr 2, 2015||FinSMEs - Correlation Ventures to Raise $170M Second Venture Capital Fund|
|Mar 31, 2015||SoCal - Tech - Correlation Ventures Seeks New, $170M Fund|